Peptira has 62 issuer-verified reports for these compounds, with reported purity of 99.571%–99.974% across 28 tirzepatide reports and 99.26%–99.975% across 34 retatrutide reports. On November 13, TIRZ-2 60 mg and RETA-3 30 mg ten-packs each included ten matching free vials. With PEPTIDEP, their totals were $1,079.10 and $899.10 respectively, before shipping and tax.
Compare Peptira's research-use TIRZ-2 and RETA-3 prices with the actual batch reports, measured fill and separate independent sample results.
In this Peptira analysis
Peptira tirzepatide and retatrutide at a glance
Peptira sells research-use tirzepatide as TIRZ-2 and retatrutide as RETA-3. Its published batch archive gives buyers an unusually useful history to inspect. We counted 28 issuer-verified tirzepatide reports and 34 retatrutide reports from Janoshik Laboratories and Freedom Diagnostics. The reports include purity and content, and many include additional panels. Peptira COA library.
The reported purity ranges are 99.571%–99.974% for tirzepatide and 99.26%–99.975% for retatrutide. The content results deserve equal attention. One 20 mg tirzepatide report measured an average of 27.65 mg, while an older 30 mg retatrutide report measured 41.21 mg. Finnrick's separate, publicly submitted samples include lower purity, low fill and an identity failure, discussed below. TIRZ20-006 report, RETA30-003 report, Finnrick test history.
On November 13, 2026, Peptira displayed buy-one-get-one offers on both product families. Code PEPTIDEP took 10% off the paid pack in the checked examples. A $1,199 TIRZ-2 60 mg ten-pack became $1,079.10 with ten matching free vials, and a $999 RETA-3 30 mg ten-pack became $899.10 with ten matching free vials. Prices, stock and promotions can change. TIRZ-2, RETA-3, Peptira coupon details.
Peptira tirzepatide and retatrutide prices
The following single-vial prices were observed on November 13, 2026. They are the listed paid-vial prices before code, shipping and tax. The storefront showed a buy-one-get-one badge for these product families, but the free quantity for each smaller pack should be confirmed in the cart. The two ten-pack examples below have separately observed quantities. TIRZ-2 product page, RETA-3 product page.
| Research product | Strength per vial | Listed single-vial price |
|---|---|---|
| TIRZ-2 | 10 mg | $89 |
| TIRZ-2 | 20 mg | $129 |
| TIRZ-2 | 30 mg | $159 |
| TIRZ-2 | 60 mg | $199 |
| RETA-3 | 10 mg | $99 |
| RETA-3 | 20 mg | $139 |
| RETA-3 | 30 mg | $179 |
The discount depends on the pack selected and the number of vials actually received. These examples compare the paid ten-pack with twenty individually priced vials of the same strength. Totals are before shipping and tax. TIRZ-2 offer, RETA-3 offer.
| Offer checked November 13 | Paid pack plus free pack | Total with PEPTIDEP | Equivalent per received vial | Saving against 20 singles |
|---|---|---|---|---|
| TIRZ-2 60 mg | 10 paid + 10 free, 1,200 mg total | $1,079.10 | $53.96 | 72.9% against $3,980 |
| RETA-3 30 mg | 10 paid + 10 free, 600 mg total | $899.10 | $44.96 | 74.9% against $3,580 |
For TIRZ-2, the paid ten-pack was $1,199. Ten percent off that pack is $119.90, leaving $1,079.10 for twenty vials when the matching free pack is included. The equivalent per vial is rounded from $53.955, or about $0.90 per labelled mg. For RETA-3, the $999 paid pack becomes $899.10 after the $99.90 code discount. A cart check showed a separate matching ten-vial pack added free, producing an equivalent $44.955 per received vial, or about $1.50 per labelled mg. The calculation applies the code to the paid pack, then divides that total by all twenty received vials. TIRZ-2, RETA-3.
The free pack is a meaningful part of those savings. Confirm that it appears in the cart, check the selected strength and review the delivered total. We did not find a published end date for the promotion. The coupon page tracks the code and offer details.
What the 28 tirzepatide reports show
The tirzepatide archive spans June 24, 2025 to August 4, 2026. It contains 28 reports for 28 lot IDs, with six from Janoshik Laboratories and 22 from Freedom Diagnostics. Four were marked current and 24 historical in our November 13 archive review. Each report includes identity, purity and measured content. Fifteen also include endotoxin, and the latest 60 mg report adds microbial DNA, elemental impurities and fentanyl testing. Peptira COA library, TIRZ60-008 report.
| Lot and report date | Labelled strength | Reported purity | Reported content | Why it matters |
|---|---|---|---|---|
| TIRZ10-001, July 14, 2025 | 10 mg | 99.840% | 9.77 mg | Historical report below its labelled amount |
| TIRZ20-004, October 24, 2025 | 20 mg | 99.935% | 19.33 mg | Historical report includes endotoxin |
| TIRZ20-006, April 2, 2026 | 20 mg | 99.92% | 27.65 mg average | About 38.3% above the labelled amount |
| TIRZ60-008, August 4, 2026 | 60 mg | 99.80% | 62.67 mg average | Three-vial result with extended panels |
TIRZ20-006 is the largest relative fill result among the tirzepatide reports we reviewed. Its high purity and high measured content answer different questions. Likewise, the older TIRZ20-004 result of 19.33 mg is about 96.7% of its 20 mg label. These are reported results for the tested samples, and they illustrate why a purity percentage alone is an incomplete way to compare a batch. TIRZ20-006, TIRZ20-004.
The TIRZ60-008 report records individual contents of 61.69, 63.48 and 62.84 mg, with 62.67 mg as the reported average. Its endotoxin replicates passed at the printed assay sensitivity, microbial DNA was not detected, the named metals were reported below limits and fentanyl was not detected. Those results apply to the named report and methods. Freedom Diagnostics TIRZ60-008.
What the 34 retatrutide reports show
The retatrutide archive spans June 26, 2025 to August 29, 2026. It contains 34 reports across 32 lot IDs, including two separately dated reports under each of RETA10-007 and RETA10-008. Nine reports are from Janoshik Laboratories and 25 from Freedom Diagnostics. Three were marked current and 31 historical when we reviewed the archive. All 34 include identity, purity and content. Twenty-two include endotoxin, eight include microbial PCR, six include elemental impurities and seven include fentanyl testing. Peptira COA library.
| Lot and report date | Labelled strength | Reported purity | Reported content | Why it matters |
|---|---|---|---|---|
| RETA10-001, June 26, 2025 | 10 mg | 99.420% | 11.23 mg | First report in this archive |
| RETA30-003, August 27, 2025 | 30 mg | 99.838% | 41.21 mg | About 37.4% above the labelled amount |
| RETA30-010, February 10, 2026 | 30 mg | 99.26% average | 31.62 mg average | Lowest reported purity in this archive |
| RETA30-015, August 29, 2026 | 30 mg | 99.87% | 33.03 mg | Listed as current in the reviewed archive |
The lowest reported retatrutide purity, 99.26%, belongs to RETA30-010. Freedom measured three vials at 99.14%, 99.24% and 99.41%, with respective contents of 31.23, 30.98 and 32.64 mg. Both endotoxin replicates passed at the stated threshold. The 99.26% figure is the report's average, so the individual results are more informative than treating it as a minimum for every vial. Freedom Diagnostics RETA30-010.
RETA30-003's 41.21 mg result against a 30 mg label is the largest relative content result in the retatrutide archive. At the other end of the relative content range, RETA20-005 measured 20.23 mg against 20 mg, about 101.2% of its label. These comparisons use the printed result or report average, not a promise about every vial in a lot. RETA30-003, RETA20-005.
Finnrick's independently submitted samples
Finnrick lists 11 tests attributed to Peptira across three compounds, with samples submitted by members of the public. Under its selected purity-focused standard, six passed and five failed. The five failures concern the two products discussed here. These samples are a separate evidence set from the vendor's named-lot reports above. Finnrick Peptira test history.
Four retatrutide samples failed Finnrick's standard. The February 22, 2026 result was 98.44% purity, the May 8 result measured 6.16 mg against a 10 mg label, the July 9 result was 99.4% purity and the September 16 result was 87.25% purity. Finnrick uses a 99.5% purity threshold in the selected mode and a fill tolerance for single-compound samples. The magnitude and nature of these findings differ, so the measured values matter more than a simple pass count. Finnrick Peptira results.
Finnrick also reported a tirzepatide identity failure on August 2. Its sample description says the vial had no label, a silver crimp and a clear cap. The sample was attributed to Peptira in Finnrick's record, but the description does not establish a labelled Peptira lot. The two later retatrutide results passed, at 99.9% purity on September 18 and 99.99% on October 27. The two other tirzepatide results, on April 23 and June 17, also passed under Finnrick's selected standard. Tirzepatide identity result, Finnrick test history.
How to read the batch evidence
Start with the product, strength, lot and report date. Peptira's library identifies current shipping batches, while earlier documents are useful for seeing how the record changed over time. A 30 mg report cannot establish the result for a 10 mg batch, and a report on several submitted vials does not mean every vial in a pack was individually tested. Peptira COA library.
Purity describes the measured peptide peak in the laboratory's analysis. Net content is the measured peptide amount, and identity establishes what the laboratory identified in the submitted sample. Endotoxin, microbial DNA, elemental impurities and fentanyl panels address different questions and are included only where the individual report shows them. Review the actual result, method and stated limit for each test rather than assuming every report has the same panel. TIRZ60-008 report, RETA30-010 report.
The issuer-verified archive is a strong documentation record, with reports across multiple batches and time periods. The independent samples are also relevant, particularly the 87.25% purity finding, the low-fill result and the identity failure. Together they make matching the exact lot and reading both the content and additional panels more useful than relying on the highest advertised purity.
How we reviewed the evidence
On November 13, 2026, we reviewed all 62 Peptira archive reports identified as tirzepatide or retatrutide, including historical and current-labelled records. Each had a matching official laboratory record in our issuer-verification review. We counted reports rather than unique lots, preserved separately dated reports bearing the same lot ID, and used each report's printed purity and content summary or average for the ranges and comparisons. Individual vial values are identified when discussed. We reviewed Finnrick's publicly submitted sample results separately and checked selected prices and cart promotion evidence on the same date. Peptira test results, Finnrick.
Peptira labels these products for research use. Our Peptira review covers the broader testing archive, business, customer feedback and operating policies. PeptidePrices may earn a commission from purchases through eligible links. See our affiliate disclosure.
Frequently asked questions
What do Peptira's tirzepatide and retatrutide COAs show?
Our November 13 review counted 28 issuer-verified tirzepatide reports and 34 issuer-verified retatrutide reports. Their reported purity ranges are 99.571%–99.974% and 99.26%–99.975%, respectively. Content and additional test panels vary by report.
What is the Peptira coupon code?
PEPTIDEP takes 10% off eligible purchases. On November 13, it also applied to the paid ten-pack in the selected RETA-3 and TIRZ-2 buy-one-get-one examples. Check the current promotion and cart before ordering.
Does a historical COA establish the results for a new order?
A report describes the submitted samples and identified lot. Match the product, strength and batch on the supplied vial to the current report, and review the actual tests and results.
What did independent testing find?
Finnrick's publicly submitted samples attributed to Peptira include four retatrutide failures and one tirzepatide identity failure under its purity-focused standard. Its two latest retatrutide samples passed. Finnrick's submitted samples are separate from Peptira's issuer-verified vendor archive.